GSK enters agreement to acquire Nuvalent, Inc. GlaxoSmithKline (GSK) has announced a $10.6 billion agreement to acquire Nuvalent, Inc., a Boston-based biopharmaceutical company specializing in oncology therapies. The deal, which includes three lung cancer assets, is designed to expand GSK’s presence in the field by addressing gaps in existing treatments for non-small cell lung cancer (NSCLC). The acquisition is expected to be accretive to GSK’s sales and core operating profit in 2027 and core earnings per share (EPS) in 2029, incorporating synergies and reprioritization of resources. The transaction encompasses two late-stage candidates for NSCLC: zidesamtinib (NVL-520), a ROS1 inhibitor, and neladalkib (NVL-655), an ALK inhibitor. Both drugs have received FDA Breakthrough Therapy and Orphan Drug Designations and are under review for potential 2026 approvals. Zidesamtinib has a target decision date of 18 September 2026, while neladalkib’s is set for 27 November 2026. If approved, these therapies could offer improved efficacy and tolerability compared to current standards, with the potential to address limitations in existing treatments. A third asset, NVL-330, is a HER2 inhibitor in phase I trials for HER2-altered NSCLC. The deal also includes Nuvalent’s preclinical pipeline, leveraging its precision medicine expertise and clinical insights from leading physician-scientists. GSK’s CEO, Luke Miels, emphasized the strategic value of the acquisition, stating that the deal aligns with the company’s focus on acquiring assets with validated targets that address unmet clinical needs. He highlighted the potential of zidesamtinib and neladalkib to provide significant new treatment options for patients with ROS1- and ALK-altered NSCLC, which primarily affect non-smoking adults aged 40-50.#gsk #nuvalent_inc #lukemiels #james_porter #iaslc_world_conference_on_lung_cancer
